Loading
Cardiovascular Disease and Adiposity / Diabetes, Cardiovascular Risks, and Lipoproteins / Adipokines, Inflammation, and Metabolic Diseases · Journal article
Quality in Sport · August 13, 2026
A consensus or society position rather than new primary data.
This is a narrative review of metabolic syndrome that synthesizes current pathophysiological understanding, diagnostic consensus criteria, and evidence-based management strategies. It does not report original research but provides a clinical framework recommending lifestyle modification (Mediterranean diet, DASH diet, structured exercise, sleep) as first-line, with GLP-1 receptor agonists and SGLT2 inhibitors as second-line pharmacotherapy.
Journal article. Individuals with metabolic syndrome.
Metabolic syndrome doubles the risk of cardiovascular events and significantly increases all-cause mortality Visceral adiposity is identified as the primary driver of systemic insulin resistance Diagnosis relies on abdominal obesity or elevated BMI plus at least two additional factors (dysglycaemia, elevated non-HDL cholesterol, high blood pressure)
Specific evidence grade or level of recommendation for pharmacotherapy not stated Prevalence trend and all-cause mortality increase cited without absolute figures or study citations
Clinicians should prioritize early, holistic intervention combining lifestyle modification (Mediterranean/DASH diet, structured exercise, sleep optimization) as first-line therapy. When lifestyle changes prove inadequate, GLP-1 receptor agonists and SGLT2 inhibitors offer evidence-supported cardio- and reno-protective benefits and should be considered to reduce multi-organ damage.
A narrative review synthesizing current understanding of metabolic syndrome pathophysiology, diagnosis, and management strategies, providing clinical recommendations rather than reporting original research data.
Quoted from the source exactly as published.
Clinicians should prioritize early, holistic intervention combining lifestyle modification (Mediterranean/DASH diet, structured exercise, sleep optimization) as first-line therapy. When lifestyle changes prove inadequate, GLP-1 receptor agonists and SGLT2 inhibitors offer evidence-supported cardio- and reno-protective benefits and should be considered to reduce multi-organ damage.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Metabolic syndrome (MetS) has emerged as one of the most critical global public health challenges of the 21st century, doubling the risk of cardiovascular events and significantly increasing all-cause mortality. Moreover, epidemiological data reflect a sharp, alarming upward trajectory in its prevalence. Pathophysiology: This review explores the synergistic pathophysiological network of MetS. Visceral adiposity acts as the primary cellular engine, driving systemic insulin resistance. In turn, these core abnormalities trigger a cascade of downstream components, including atherogenic dyslipidaemia (the "lipid triad"), neuroendocrine-driven arterial hypertension, and systemic pro-inflammatory and pro-thrombotic states. Diagnosis: We outline the evolution of diagnostic criteria. The consensus relies on abdominal obesity or elevated BMI as a basic criterion, combined with at least two additional factors (dysglycaemia, elevated non-HDL cholesterol, and high blood pressure). Therapeutic Strategies: Non-pharmacological lifestyle modification — specifically the Mediterranean and DASH diets, structured aerobic and resistance training, and proper sleep hygiene — remains the absolute cornerstone of management. When lifestyle modifications fall short, modern pharmacotherapy, particularly GLP-1 receptor agonists and SGLT2 inhibitors, offers profound, synergistic cardio- and reno-protective benefits. Conclusions: Halting the progressive multi-organ damage of metabolic syndrome requires early, holistic clinical intervention. The combination of targeted behavioural strategies and novel, organ-protective pharmacotherapies provides a powerful approach to reversing the metabolic cascade and reducing cardiovascular risk.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.